LM van Velsen, et al. Gut Published Online First: 18 September 2026. doi: 10.1136/gutjnl-2026-338784. Open access! High rates of transition to immune active disease in a cohort of strictly defined immune tolerant patients with chronic hepatitis B: results from the RADICAL consortium
Methods: “This is a multicentre cohort study based on results from the RADICAL consortium, which includes data from patients with CHB from various sites in North America, Europe and Asia. All patients had CHB (hepatitis B surface antigen (HBsAg) positive for >6 months) without HCV, HDV or HIV co-infections…The IT [immune tolerant] phase was defined as persistently (1) HBeAg-positive, (2) ALT ≤40 U/L, (3) HBV DNA >7 log10 IU/mL, (4) minimal fibrosis. 951 IT patients were included with a median age of 33, 40% were male with a median follow-up of 13 years.”
Key findings:
- Median ALT and HBV DNA at baseline were 25.5 U/L and 8.4 log10 IU/mL.
- The probability of transitioning to immune active (IA) disease was 51%, 67% and 72% before 5 years, 10 years and 15 years.
- The 5-year, 10-year and 15-year cumulative probabilities of transition to IA disease were highest in patients with ALT >30 U/L (87%, 89% and 89%) compared with patients with an ALT ≥20 and ≤30 U/L (58%, 70% and 73%) and an ALT <20 U/L (39%, 55% and 62%) at baseline.
- IT patients had a low risk of progression to significant fibrosis (15 years: 6.3%), and HCC (15 years: 1.1%).

This was defined by initiation of AVT with an ALT <50 U/L.
My take: This study shows the need to continue to monitor patients with immune-tolerant disease; an immune-active disease state commonly develops and merits antiviral therapy. Also, see the recent blog post on 11/6/26 (Hepatitis B Therapy for Patients with Mildly Elevated Liver Enzymes Associated with Lower Risk of Cancer and Cirrhosis) indicating that HBV treatment in patients with mild LFT elevation improves outcomes.
Related blog posts:
- Bepirovirsen: Breakthrough for Chronic Hepatitis B Infection
- Major Update on AASLD IDSA Practice Guideline on Treatment of Chronic Hepatitis B (Part 1)
- Major Update of AASLD IDSA Practice Guideline on Treatment of Chronic Hepatitis B (Part 2)
- Scientific Basis for Current Hepatitis B Vaccine Strategy (2025)













